The calendar shows Q3. The molecule has cleared target identification. Downstream assay development is ready to begin. But the translational research team is still waiting on cohort data — and has been waiting since Q1. This is not an edge case. It is the operational baseline for a substantial share of early-stage drug discovery programs.
Biobanks hold one of the most valuable raw materials in modern medicine: longitudinally collected, phenotypically characterized, consented biological samples paired with clinical records. Yet translating that collection into a usable dataset for a specific research question remains an obstacle course that costs programs months they don't budget for. Understanding why requires looking at how biobank data infrastructure developed historically — and where the structural mismatches sit today.
How Biobanks Were Built — and Why That Creates Friction Now
Most large biobank collections were established with academic research as the primary beneficiary. The operating model was built around investigator-initiated proposals, committee review, data use agreements drafted between institutions, and sample shipments coordinated by curators who also held faculty positions. Speed was not a design criterion. Scientific rigor and ethical oversight were.
That original design served its purpose well: it produced collections of genuine scientific depth, with rich phenotypic annotation and decades of follow-up in some cases. Population cohort programs across the US and Europe accumulated hundreds of thousands of participants precisely because they were taken seriously as long-term scientific infrastructure, not commercialized prematurely.
The mismatch emerged when the biopharma industry began treating those same collections as a potential source of real-world data for drug discovery programs operating on 12-to-18-month decision cycles. Academic biobanks are not slow because of carelessness — they are slow because their governance was designed for a different requester type, a different timeline, and a different accountability structure.
Three Structural Gaps That Compound Each Other
When a biopharma research operations team attempts to source a specific cohort — say, treatment-naive patients with a particular metabolic phenotype, genomic variant, and three-year follow-up on a cardiometabolic endpoint — the request typically stalls at one of three points, and frequently at all three.
The consent chain is incomplete or ambiguous
Many biobank collections were built under narrow consent forms that did not anticipate commercial licensing. The consent may permit academic research broadly but is silent on industry use, or permits "research" without defining whether proprietary drug discovery qualifies. In practice, this means data custodians face a legal question before they can respond to a data request — and that question requires IRB counsel review, not just a dataset export.
Consider a hypothetical scenario that reflects a pattern we hear across research operations conversations: a growing biopharma team in the Boston area, 2023, attempting to source a neurological phenotype cohort for a target validation program. They identified a collection with the right phenotypic depth and longitudinal follow-up. The consent documentation, collected between 2009 and 2014, used language that was standard at the time but predated common broad consent frameworks. What followed was eight weeks of legal review, a re-consent feasibility assessment, and ultimately a determination that only a subset of participants could be included — reducing the effective cohort size by roughly a third. The program timeline absorbed the delay, but the project confidence interval widened considerably.
Data is collected but not curated to a licensable standard
Raw biorepository exports are rarely in a state that meets what a research data buyer actually needs. Clinical phenotype data arrives in heterogeneous formats — multiple EHR generations, free-text procedure notes, ICD-9 and ICD-10 codes mixed without crosswalk documentation. Genomic data may have been processed with pipeline versions that are no longer reproducible. Sample metadata may have gaps in collection site, processing interval, or freeze-thaw cycle records that matter for downstream proteomics or transcriptomics analysis.
None of these are failures of the biobank. They are the natural consequence of collections assembled over years, often across multiple institutions, using the infrastructure available at the time. But for a research program trying to move from data acquisition to analysis in weeks, the cleaning and harmonization work that turns a biorepository export into a usable dataset can consume more calendar time than the analysis itself.
De-identification and documentation are not consistent across collections
The de-identification burden varies significantly depending on the collection's origin, the intended use, and the buyer's legal team's risk threshold. Some collections were de-identified under the HIPAA Safe Harbor method, removing 18 specified identifier types, with clear documentation. Others used expert determination approaches, which can produce stronger statistical guarantees but require attestation documentation that may or may not have been preserved. Still others used internal institutional standards that predate formal HIPAA guidance and may not satisfy current data room review.
When a biopharma legal team opens a data room for a licensing transaction, they are not just checking whether the data looks de-identified — they are checking whether the documentation chain supports that claim. If the de-identification methodology can't be traced back to a documented procedure with an accountable signatory, the legal review process stalls, regardless of the data's scientific quality.
What a Licensing-First Model Changes — and What It Doesn't
The premise behind building a licensing-first data infrastructure layer is that the bottleneck is not the underlying data — it's the readiness of that data for a commercial transaction. If consent chains, de-identification documentation, phenotype harmonization, and format standardization are handled upstream, before a research team submits a request, the timeline compresses dramatically.
We're not suggesting that all biobank data should be pre-packaged for commercial licensing regardless of consent or scientific context. That would invert the ethical framework that makes biobank collections trustworthy in the first place. The point is narrower: for collections where the consent architecture permits commercial research use, building a proper curation and documentation layer upstream — rather than asking each data requester to negotiate and rebuild that layer from scratch — removes redundant work without compromising oversight.
The practical difference for a research operations team is the ability to evaluate a dataset's fitness for purpose before engaging in a weeks-long legal review process. If provenance metadata, consent scope, de-identification method, and phenotype completeness statistics are documented and available as part of the dataset record, the decision to request data can be made in days rather than months.
The Real-World Data Dimension
One often-underappreciated aspect of the biobank data gap is the longitudinal follow-up problem. Many drug discovery programs require not just a cross-sectional phenotype snapshot but evidence of outcome trajectories over two to five years. Real-world data from claims or EHR sources can provide breadth, but biobank collections uniquely offer sample-linked longitudinal data — the ability to connect a baseline genomic or proteomic measurement to a clinical outcome observed years later in the same individual.
That scientific depth is exactly what makes biobank data irreplaceable for certain research questions. It's also what makes the data gaps particularly damaging: a cohort that is almost right — the right phenotype, the right variant, but missing two years of follow-up or collected at an institution with incomplete outcome ascertainment — forces a research team into a long chain of tradeoff decisions that none of them should have to make at the start of a program.
The Practical Implication for Research Operations Teams
The structural gaps described here are not going to be solved by any single technology platform. IRB governance, consent scope, and de-identification documentation are human processes with institutional dependencies that take years to change at a systemic level. What can change more quickly is how those processes are bundled and presented to research buyers.
The research operations teams we talk to aren't asking for a magic solution to biobank governance. They are asking for a way to know, before investing four months in a data request process, whether a collection has the consent scope, de-identification documentation, and phenotypic completeness that their program requires. That is a solvable information problem — and one that the current structure of biobank data access does almost nothing to address.
Until that information is systematically surfaced upstream, the calendar will keep showing Q3 while the translational team waits for data that should have been ready in Q1.
